HK1243921A1 - 用於緩解尿頻的延長釋放製劑及其使用方法 - Google Patents

用於緩解尿頻的延長釋放製劑及其使用方法

Info

Publication number
HK1243921A1
HK1243921A1 HK18103371.3A HK18103371A HK1243921A1 HK 1243921 A1 HK1243921 A1 HK 1243921A1 HK 18103371 A HK18103371 A HK 18103371A HK 1243921 A1 HK1243921 A1 HK 1243921A1
Authority
HK
Hong Kong
Prior art keywords
urination
extended
frequency
reducing
release formulation
Prior art date
Application number
HK18103371.3A
Other languages
English (en)
Inventor
大衛．A．迪爾
Original Assignee
韋爾斯利醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by 韋爾斯利醫藥有限公司 filed Critical 韋爾斯利醫藥有限公司
Publication of HK1243921A1 publication Critical patent/HK1243921A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18103371.3A 2012-03-19 2018-03-10 用於緩解尿頻的延長釋放製劑及其使用方法 HK1243921A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
HK1243921A1 true HK1243921A1 (zh) 2018-07-27

Family

ID=49223209

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15105034.0A HK1204553A1 (zh) 2012-03-19 2015-05-27 用於緩解尿頻的延長釋放製劑及其使用方法
HK18110965.0A HK1251469A1 (zh) 2012-03-19 2015-05-27 用於緩解尿頻的延長釋放製劑及其使用方法
HK18103371.3A HK1243921A1 (zh) 2012-03-19 2018-03-10 用於緩解尿頻的延長釋放製劑及其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK15105034.0A HK1204553A1 (zh) 2012-03-19 2015-05-27 用於緩解尿頻的延長釋放製劑及其使用方法
HK18110965.0A HK1251469A1 (zh) 2012-03-19 2015-05-27 用於緩解尿頻的延長釋放製劑及其使用方法

Country Status (15)

Country Link
EP (2) EP2827852A4 (zh)
JP (5) JP2015510928A (zh)
KR (4) KR20140134333A (zh)
CN (4) CN104302284A (zh)
AU (4) AU2013235518B2 (zh)
BR (2) BR112014020271A8 (zh)
CA (2) CA2866853A1 (zh)
HK (3) HK1204553A1 (zh)
MX (3) MX2014011128A (zh)
MY (2) MY174090A (zh)
NZ (6) NZ630471A (zh)
RU (3) RU2669565C2 (zh)
SG (2) SG11201500408VA (zh)
WO (2) WO2013142197A1 (zh)
ZA (2) ZA201405862B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
ES2910361T3 (es) 2013-07-23 2022-05-12 Serenity Pharmaceuticals Llc Composiciones que comprenden desmopresina en combinación con un agonista del receptor adrenérgico beta-3
JP2017516832A (ja) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法
KR101809908B1 (ko) 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
AU2015349811B2 (en) * 2014-11-20 2021-05-06 Acerus Pharmaceuticals USA, LLC Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
JP2018529710A (ja) * 2015-09-30 2018-10-11 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿の頻度を低減するための組成物、ならびにその作製および使用方法
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2320193A1 (en) * 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CN1633283A (zh) * 2002-02-19 2005-06-29 法玛西雅公司 环加氧酶抑制剂和抗蕈毒碱试剂用于治疗失禁的用途
US20060035923A1 (en) * 2002-06-07 2006-02-16 Rian Van Meeteren Overactive bladder treating drug
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
BR0318201A (pt) * 2003-03-21 2006-03-21 Mcneil Ppc Inc regime de dosagem de fármaco antiinflamatório não-esteroidal
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US8685924B2 (en) * 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
KR20080043763A (ko) * 2005-06-17 2008-05-19 다이나미스 테라퓨틱스, 인코포레이티드 염증성 상태의 치료
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
JP5312027B2 (ja) * 2005-09-02 2013-10-09 セラヴィダ、インク 病気の治療法
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
AU2013235518A2 (en) 2014-10-09
NZ718163A (en) 2017-09-29
KR20190003840A (ko) 2019-01-09
AU2013235507A1 (en) 2014-08-21
BR112014020113A2 (zh) 2017-06-20
JP2018024693A (ja) 2018-02-15
MY174090A (en) 2020-03-09
RU2014142066A (ru) 2016-05-10
JP2015510936A (ja) 2015-04-13
NZ628079A (en) 2016-05-27
ZA201406146B (en) 2016-08-31
RU2014142025A (ru) 2016-05-10
NZ714288A (en) 2016-12-23
SG11201500408VA (en) 2015-03-30
RU2669565C2 (ru) 2018-10-12
WO2013142197A1 (en) 2013-09-26
EP2827852A1 (en) 2015-01-28
MX2014011128A (es) 2015-08-10
EP2827852A4 (en) 2016-03-02
ZA201405862B (en) 2016-08-31
AU2017203139A1 (en) 2017-06-01
RU2599017C2 (ru) 2016-10-10
NZ714662A (en) 2016-08-26
WO2013142274A1 (en) 2013-09-26
RU2016133305A (ru) 2018-12-10
SG11201500409SA (en) 2015-03-30
AU2013235518B2 (en) 2017-03-02
CA2866755A1 (en) 2013-09-26
CN107157991A (zh) 2017-09-15
MX2019008817A (es) 2019-09-26
AU2017203139B2 (en) 2018-07-19
KR20140134333A (ko) 2014-11-21
HK1251469A1 (zh) 2019-02-01
KR20170015537A (ko) 2017-02-08
KR20140134284A (ko) 2014-11-21
CN104321056A (zh) 2015-01-28
BR112014020113A8 (pt) 2017-07-11
JP2015510928A (ja) 2015-04-13
JP2018138602A (ja) 2018-09-06
AU2017203246B2 (en) 2018-10-18
EP2827851A1 (en) 2015-01-28
AU2017203246A1 (en) 2017-06-08
AU2013235518A1 (en) 2014-09-25
BR112014020271A8 (pt) 2017-07-11
HK1204553A1 (zh) 2015-11-27
CN107789626A (zh) 2018-03-13
MX2014011129A (es) 2015-08-10
CN104302284A (zh) 2015-01-21
MY175764A (en) 2020-07-08
BR112014020271A2 (zh) 2017-06-20
CA2866853A1 (en) 2013-07-26
RU2016133305A3 (zh) 2018-12-10
EP2827851A4 (en) 2015-10-14
AU2013235507B2 (en) 2017-03-23
JP2016172752A (ja) 2016-09-29
NZ712594A (en) 2016-09-30
NZ630471A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
IL274404A (en) Body expandable device and method for use
IL261768B (en) Devices and methods for tissue treatment
HK1243921A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
IL232715A0 (en) The delayed-release composition for reducing the frequency of urination and a method for using it
HK1200690A1 (zh) 可膨脹體裝置和使用方法
ZA201403762B (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
EP2709562A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
HUE044081T2 (hu) C4 Monometil-triterpenoid-származékok, és módszerek azok alkalmazására
EP2613735A4 (en) DEVICES AND METHODS FOR THE TREATMENT OF VASCULAR ABNORMALITIES
EP2825242A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS
EP2790709A4 (en) HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF
EP2938289A4 (en) DEVICES AND METHODS FOR TREATING VASCULAR DEFECTS
IL261232A (en) A pharmaceutical formulation for reducing urinary frequency and a method for its use
HK1249438A1 (zh) 用於緩解尿頻的緩釋製劑及其使用方法
HK1203395A1 (zh) 用於評價活性劑的可植入裝置和方法
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1248549A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
HK1203159A1 (zh) 用於壓力性尿失禁的預防劑和/或治療劑
AP3759A (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same